glp-1 prescriptions growth slowdown 2024 RA prescription trends: January 2018 – December Obesity GLP-1 Market

We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein

For drugmakers, the shift brings obesity treatment further into mainstream retail, making big-box players more important partners for patient adherence, engagement, and long-term outcomesnot just prescription volume

As interest in GLP-1 medication grows, scammers are tricking consumers with fake alternatives

P =0.69, high certainty of evidence), and GLP-1RA (RR, 0.97

Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy

In phase II and III trials, 5.1% of the patients receiving exenatide twice-daily, 16% of those receiving exenatide once-weekly, 3.9% of those receiving lixisenatide, and 15% of those receiving albiglutide experienced injection site reactions [48, 105, 106, 110]